SUPPLEMENTARY FILE 1: Study Protocol for Fish oil in knee osteoarthritis: A randomised clinical trial of low dose versus high dose (also known as the FOSTAR study).


STUDY DESIGN

The FOSTAR study is a randomised double-blind controlled clinical trial of 200 subjects with symptomatic knee osteoarthritis from three Australian centres (The Queen Elizabeth Hospital, Adelaide, South Australia; Menzies Research Institute, Hobart, Tasmania and Royal North Shore Hospital, Sydney, New South Wales). Participants will be recruited and randomly allocated to either high or low dose fish oil, following completion of a one month run-in period.

All participants will provide written informed consent. The study has been approved by The Queen Elizabeth Hospital, Royal North Shore Hospital and Tasmanian Human Research Ethics Committees. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN 12607000415404) on 19th August 2007.

The proposed flow of subjects through the study is shown in Figure 1.

Figure 1. Flow of subjects through the FOSTAR study



RECRUITMENT

Subjects will be recruited at three centres through patient databases currently held by study

Investigators and direct advertising in local newspapers and Arthritis Australia newsletters.

INCLUSION CRITERIA

The inclusion criteria required (i) age greater than 40 years (ii) clinical knee OA defined using American College of Rheumatology criteria [1] and (iii) VAS knee specific pain score greater than 20mm (0-100mm scale). The knee which is most symptomatic knee, as determined by the participant, will represent the 'index' knee for the remainder of the study.

EXCLUSION CRITERIA

Exclusion criteria included (i) dementia or inability to give informed consent, (ii) pregnancy or lactation, (iii) severe knee OA (Grade 3 radiographic joint space narrowing using the Osteoarthritis Research Society International atlas), (iv) planned knee replacement surgery, (v) long-term use (\geq 6 months) of anti-inflammatory dose of fish oil (15mL of oil or \geq 9 capsules), (vi) presence of inflammatory arthritis and (vii) contra-indications to MRI.

RUN-IN PERIOD

Once volunteers have been screened, they will enter a 4-week pre-randomisation run-in period to exclude participants intolerant to taking liquid oil. All subjects will be instructed to take 15 ml daily of a similarly flavoured oil (citrus flavoured Sunola oil). While the exact contents of this preparation will not be revealed, it will be explained to participants that this preparation is designed to test common aspects of the interventions, but differs from the actual test oil preparations. A standardized instructional video demonstrating a method of taking liquid oil that enhanced tolerability by 'layering' on juice will be shown to all participants prior to run-in. Participants will be instructed to take the test oil on juice using the two glass technique [2]. Briefly, one of two shot glasses is filled with fruit juice and the other half filled with juice. The required dose of oil is then measured and layered onto the juice in the half filled glass. Without stirring, the contents are then swallowed in a single gulp. Immediately thereafter, the glass of juice alone is sipped slowly over a period of about 15 seconds. The oil and juice is taken with a meal and not on an empty stomach. Carbonated drinks are avoided. The oil can be taken in divided doses. This method has generally been effective in avoiding a 'repeating' fish oil taste.

Patients will be reviewed in the 3rd week after commencing the run-in oil. Subjects who do not attend the appointments or are non-compliant (who consume less than 75% of the oil as assessed by volume) or are intolerant of the oil will not be randomised. The requirements

for the run-in test (and the consequences of failing) will be disclosed to the subjects prior to screening. During this run-in period, subjects will be asked to cease fish oil and glucosamine but will be permitted to take paracetamol for first line analgesia and NSAID (ibuprofen up to 400mg QID if required) for second line analgesia. In our experience about 20% of subjects recommended fish oil fail to establish a pattern of daily ingestion. This period will establish the patient's ability to take a test oil preparation using the recommended oil on juice technique as well as tolerance to and adequacy of rescue analgesia, including, if required, the selected NSAIDs. None of these medications, including the 'run-in' oil will be taken in the week prior to the baseline assessment, when randomisation and commencement of the allocated test preparation will take place. The use of a run-in has been used to improve compliance and retention in RCTs [3]

RANDOMIZATION BY CENTRE

Subjects who satisfy compliance criteria and VAS pain score criteria during the run-in period will be randomised (1:1) to one of the two arms of the RCT. The randomisation will be done centrally at The Queen Elizabeth Hospital in Adelaide by computer generated random numbers and will be stratified by centre.

INTERVENTION

Participants will be randomly allocated to one of two treatment arms:

- 1. Anti-inflammatory dose of fish oil, 15 ml/day (high dose fish oil)
- 2. Comparator oil comprising 10% fish oil in sunola oil, 15 ml/day (low dose fish oil)

High dose fish oil contains EPA 18% and DHA 12%, supplying 4.5g EPA+DHA per day. The low dose comparator oil, a blend of fish oil and high oleic sunola oil in a ratio of 1:9, supplies 0.45g EPA + DHA per day, which is equivalent to 1.5 standard 1g fish oil capsule daily. Both oils are flavoured with citrus oils and will be provided in identical dark 500mL bottles. Fish oil is sourced from Berg LipidTech Aalesund, Norway. The oils, blending, masking and bottling is performed by Melrose Health, Victoria, Australia. Study oil bottles will be returned at each study visit and volume of unconsumed oil measured to assess compliance. The presence of fish oil in the comparator will obviate the ethical problem of denying patients n-3 fatty acids that are recommended for cardiovascular health and will also add 'fishy' sensate properties that will militate against unmasking. We have previously shown addition of citrus flavouring to fish oils and vegetable oils achieves masking. The EPA and

DHA dose in the undiluted test fish oil has been shown to have anti-inflammatory effects in a variety of clinical settings, whereas the comparator oil will deliver a dose of fish oil that is well below the minimum amount (10ml/d) that has been associated with anti-inflammatory effects in RCTs. Participants will be provided with paracetamol (500mg) tablets with instructions that they could safely use up to 8 per day.

Participants will undergo assessments at baseline, 6 weeks, 3, 6, 9, 12, 18 and 24 months with interim phone calls to participants to encourage continuing compliance and participation

Dietary and general advice:

Subjects will be instructed to use olive oil based products (spreads, cooking oils, dressings etc), where possible, to minimise variation in consumption of n6 polyunsaturated fatty acids which compete with dietary n3 fatty acids. Written instructions regarding technique for taking the oil and directions for the background diet will be provided. All participants will also be given written information on knee osteoarthritis and generic instructions regarding exercises appropriate for maintaining knee function in OA and general fitness. The package of informed consent and written advice will include information regarding potential unwanted effects of fish oil and paracetamol.

COMPLIANCE

The degree of compliance with test oils will be measured in two ways: (i) calculation of consumed fish oil by count of bottles provided and measurement of oil remaining in returned partly used bottles and (ii) fasting plasma omega-3 fatty acid analysis. These assessments will be undertaken at 3, 6, 12, 18 and 24 months. The plasma fatty acid analysis results will not be available to subjects or investigators till the completion of the study.

OUTCOME MEASURES

Primary outcomes:

- 1. Pain (WOMAC NRS 3.1 index [4], 10 point numerical scale) at 3, 6, 9, 12 and 24 months (knee specific)
- 2. Change in knee MRI cartilage volume at 2 yrs.

Secondary outcomes:

 Disability (WOMAC NRS 3.1 index [4], 10 point numerical scale) at 3,6, 9,12 and 24 months (knee specific)

- 2. Quality of life (AQOL) [5]
- 3. Analgesic use, measured using a daily diary (NSAID) and paracetamol (pill count at each visit)
- 4. Change in MRI scores of bone marrow lesions at 2 years
- 5. Safety assessments/adverse events

In addition to the designated outcome measures, blood pressure, full blood count and electrolytes and liver function testing, presence of comorbidities (eg renal disease, cardiovascular disease, peptic ulcer disease) and a diet questionnaire, DQES V2[6], used to assess n-3 and n-6 fatty acid intake in usual diet, will be assessed at baseline.

As the study will extend over two years in a population at an age at risk for cardiovascular disease and declining bone density, routine investigations will be undertaken at baseline and two years to monitor collateral health effects and risks including:

- 1. fasting blood lipids
- 2. low titre c-reactive protein
- 3. bone mineral density of hip and spine
- 4. lung spirometry (The Queen Elizabeth Hospital participants only)

The assessment schedule is summarized in Table 1, and data collection forms are presented in Appendix 1.

FOSTAR STUDY ASSESSMENTS								
	Enrolment	Ransomisation	Treatment				Completion	
	Visit 1 (-4 weeks)	Visit 2 (0 weeks)	Visit 3 (3 month)	Visit 4 (6 month)	Visit 5 (9 month)	Visit 6 (12 month)	Visit 7 (18 month)	Visit 8 (24 month)
Informed Consent for FOSTAR	X	(o weeks)						
Medical History	Х							
Surgical History	Х	Х	Х	Х	Х	Х	Х	Х
OA History		Х						
Inclusion/Exclusion Criteria	Х	Х						
Concomitant medications	Х	Х	Х	Х	Х	Х	Х	Х
Physical Exam/Vital Signs	Х	Х	Х	Х	Х	Х	Х	Х
Fish Oil Dosing DVD	Х	Х						
Run-In Fish Oil	Х							
Diet information sheet		Х						
Exercise information sheet		Х						
Osteoarthritis Information sheet		Х						
Laboratory testing								
Blood sampling for FBC, CRP, LFT		Х				Х		Х
electrolytes and fasting lipids								
Blood sampling for serum fatty		Х	Х	Х	Х	Х	Х	Х
acids								
Imaging								
Knee X-ray	Х							
MRI scan		Х						Х
DEXA scan		Х						Х
Questionnaires								
WOMAC Questionnaire	Х	Х	Х	Х	Х	Х	Х	Х
NRS pain Questionnaire	Х	Х	Х	Х	Х	Х	Х	Х
MAPT Questionnaire		Х				Х		Х
AQoL Questionnaire		Х	Х	Х	Х	Х	Х	Х
Diet Questionnaire		Х						Х
Analgesic Medication		Х	Х	Х	Х	Х	Х	
Take-Home Diary	Х	Х	Х	Х	Х	Х	Х	
Randomisation		Х		ļ		ļ		
Study Fish Oil		Х	Х	Х	Х	Х	Х	
Pedometer Readings		Х						Х

Table 1. Schedule of assessment for primary and secondary outcome measures

MRI scanning and scoring:

MRI scans will be performed at each of the study centres. MRI will be performed on the most symptomatic knee as determined by the participant, and will represent the 'index'

knee for the remainder of the study. Each participant will have an MRI performed on their 'index' knee at baseline and after 2 years. The 'index' knee will be imaged in the sagittal plane on the same model 1.5T whole-body MR unit using a commercial receive-only extremity coil. The following sequence and parameters will be used: a T1-weighted, fat-suppressed, 3-dimensional gradient recall acquisition in the steady state; flip angle 55 degrees; repetition time 58 msec; echo time 12 msec; field of view 16 cm; 60 partitions; 512 × 192 matrix; one acquisition time 11 minutes, 56 seconds. Sagittal images will be obtained at a partition thickness of 1.5 mm and an in-plane resolution of 0.31 × 0.83 mm (512 × 192 pixels).

The MRI scans will be assessed by a single trained observer. Each participant's baseline and follow-up MRI scans will be scored unpaired with blinding to subject identification and timing of MRI. The volumes of individual cartilage plates (medial tibia, lateral tibia and patella) will be isolated from the total volume by manually drawing disarticulation contours around the cartilage boundaries on a section by section basis. These data will then be resampled by means of bilinear and cubic interpolation (area of 312 mm and 1.5 mm thickness, continuous sections) for the final 3D rendering. The coefficient of variation for this method in our hands is 2.1% to 2.6% [7].

Bone marrow lesions (BMLs) will be assessed on a proton density-weighted fat saturation 2D fast spin echo sequence in the sagittal plane. They will be defined as areas of increased signal adjacent to the subcortical bone at the medial tibial, medial femoral, lateral tibial, lateral femoral, superior patella and inferior patella sites. One trained and blinded observer will score BMLs by measuring the maximum area of the lesion (mm²) at baseline and follow-up, as previously described [8]. The intraclass correlation coefficient (ICC) in our hands for this method of measurement is 0.97 [8].

Radiographic assessment:

Radiographs will only be used as a screening tool at participant recruitment, and not as an outcome measure. Radiographs of the index knee in the Buckland-Wright view will be taken at baseline, to allow comparison with MRI assessments and as this is putatively the most reproducible technique with regard to non-fluoroscopic positioning [9].

Radiographs will scored independently by 2 trained observers at each site using a published atlas to classify disease in the tibiofemoral joint. The radiographic features of tibiofemoral

OA will be graded in each compartment on a 4-point scale (0-3) for individual features of osteophytes and joint space narrowing [10]. We have shown previously high degrees of intra-observer and inter-observer reproducibility for agreement on features of OA in the knee with regard to both osteophytes and joint space narrowing [11].

Success of Blinding:

Success of blinding will be assessed by asking the participants the following question:

"If you were asked which oil you were taking during the FOSTAR study would you say? Possible responses: Low dose, comparison oil OR high dose fish oil OR I am not sure which oil I may have been taking". This will be asked at final visit.

ANALYSIS PLAN

Both intention-to-treat and per protocol analyses will be undertaken. Multiple imputation will be used for missing data. Analyses will be performed using longitudinal mixed model regression. The primary interpretation will be the comparison between the two treatment groups at the end of study.

SAMPLE SIZE CONSIDERATION

Sample sizes of 100 per treatment group were selected based on power calculations for longitudinal (ie repeated data) data with 6 treatment visits, $\alpha = 0.05$, $\beta = 0.2$, an attrition rate of 5% per visit, and a standardised treatment effect at the end of the study of 0.4 (i.e. a medium effect).

WITHDRAWALS

All participants will be followed for the duration of the two year study, irrespective of whether they discontinue the study oil (unless they decide to withdraw consent).

REFERENCES

1. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986 Aug; 29(8):1039-1049.

2. Cleland LG, James MJ, Proudman SM. Fish oil: what the prescriber needs to know. Arthritis Res Ther. 2006; 8(1):202.

3. Lang JM. The use of a run-in to enhance compliance. Stat Med. 1990 Jan-Feb; 9(1-2):87-93; discussion 93-85.

4. Bellamy N. WOMAC Osteoarthritis Index User Guide. Version VIII. Brisbane, Australia, 2007.

5. Whitfield K, Buchbinder R, Segal L, Osborne RH. Parsimonious and efficient assessment of health-related quality of life in osteoarthritis research: validation of the Assessment of Quality of Life (AQoL) instrument. Health Qual Life Outcomes. 2006; 4:19.

6. Giles GG, Ireland PD. Dietary Questionnaire for Epidemiologic Studies (Version 2). Cancer Council Victoria. 1996.

7. Jones G, Glisson M, Hynes K, Cicuttini F. Sex and site differences in cartilage development: a possible explanation for variations in knee osteoarthritis in later life. Arthritis Rheum. 2000 Nov; 43(11):2543-2549.


8. Dore D, Quinn S, Ding C, Winzenberg T, Zhai G, Cicuttini F, et al. Natural history and clinical significance of MRI-detected bone marrow lesions at the knee: a prospective study in community dwelling older adults. Arthritis Res Ther. 2010; 12(6):R223.

9. Wolfe F, Lane NE, Buckland-Wright C. Radiographic methods in knee osteoarthritis: a further comparison of semiflexed (MTP), schuss-tunnel, and weight-bearing anteroposterior views for joint space narrowing and osteophytes. J Rheumatol. 2002 Dec; 29(12):2597-2601.


10. Burnett S. A radiographic atlas of osteoarthritis. London: Springer-Verlag, 1994.

11. Wluka AE, Stuckey S, Snaddon J, Cicuttini FM. The determinants of change in tibial cartilage volume in osteoarthritic knees. Arthritis Rheum. 2002 Aug; 46(8):2065-2072.

APPENDIX 1: FOSTAR STUDY DATA COLLECTION FORMS



A two year, multi-centre, double-blinded, randomised, controlled clinical trial to assess the benefits of high-dose oral fish oil in patients experiencing symptomatic knee osteoarthritis.



Randomisation Number:



Subject Initials:

Study Selected Knee:

FOSTAR STUDY ASSESSMENTS								
Shaded areas are specific to TQEH site ONLY	Enrolment	Randomisation		Treatment				Completion
	Visit 1 (-4weeks)	Visit 2 (0weeks)	Visit 3 (3month)	Visit 4 (6month)	Visit 5 (9month)	Visit 6 (12month)	Visit 7 (18month)	Visit 8 (24month)
Informed Consent for FOSTAR	X							
Informed Consent for PFT sub-study	X							
Informed Consent for DNA sub-study	X							
Medical History	Х							
Surgical History	Х	X	Х	Х	Х	X	Х	Х
OA History		X						
Inclusion/Exclusion Criteria	Х	X						
Concomitant medications	Х	X	Х	Х	Х	Х	Х	Х
Physical Exam/Vital Signs	Х	X	Х	Х	Х	Х	Х	Х
Serum Pregnancy Test		X						Х
Blood sampling for FBC, CRP, LFT		Х				Х		Х
electrolytes and fasting lipids								
Blood sampling for serum fatty acids		X	Х	Х	Х	Х	Х	Х
Blood sampling for DNA sub-study		X						
Lung Function sub-study test		X				X		Х
Knee X-ray (if required)	Х							Х
MRI scan		X						Х
DEXA scan		X						Х
WOMAC Questionnaire	Х	X	Х	Х	Х	X	X	Х
NRS pain Questionnaire	Х	Х	Х	Х	Х	Х	Х	Х
MAPT Questionnaire		X				X		Х
AQoL Questionnaire		X	Х	Х	Х	X	Х	Х
Diet Questionnaire		X						Х
CES-D Questionnaire (Depression)		Х				Х		Х
Fish Oil Dosing DVD	Х	X						
Run-In Fish Oil	X							
Analgesic Medication		X	X	X	X	X	X	
Take-Home Diary	X	X	X	X	X	X	X	
Randomisation		X						
Study Fish Oil		X	X	X	X	Х	X	
Diet information sheet		X						

FOSTAR STUDY

NHMRC Grant Approval Number 451900

Site Number:	Randomisation Number:								
Subject Initials:									
Exercise information sheet	2								
Osteoarthritis Information sheet		<u> </u>						V	
Pedometer Readings		<u> </u>						X	
	FOS	T A	AR ST	UDY					
Visit 1	– ENR	OL	LMEN	Т					
Visit Date]	
				INFO	DRME	D CON	NSEN'	Г	
								- -	
Date Written Informed Consent O	btained			D/MN	/ ⁄/YYY	L			
						Ye	s N	0	
Has a copy been provided to the s	ubject for	the	eir recor	ds					
Has a copy been added to the subj	ects hosp	ital	records]		
\Box Has the original been filed in the s	subjects C	RF	7						
					DEM	OGRA	PHIC	S	
Date of Birth] [] / /YYY]	~	
Gender			Fei	male					
				ale					

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:
Ethnic Origin	
	Asian
	Hispanic
	Other (specify below)

	SURGICAL HISTORY
Previous Surgical Procedures	Date of Procedure
	(DD/MM/YYYY)
If the subject is currently taking any medications for any of the al	pove procedures, ensure that
details are recorded in the Concomitant Medications record.	

			CO-MORBID	ITIES
Have you ever been told by a Dr or a	If yes, Do you currently			
any of the following conditions?	have these condition	ons?		
	YES	NO	YES	NO
Diabetes				
Osteoporosis				
High Blood Pressure				
Asthma				

Site Number:	Randomis	sation N	Number:	
Subject Initials:	Study Sele	cted K	nee:	
Bronchitis				
Emphysema/Chronic bronchitis				
Stroke				
Heart Attack				
Angina				
High Cholesterol				
None of the above				

		MEDICAL HIGTODY
		MEDICAL HISTORY
CURRENT MEDICAL	Date of Onset	Date Resolved Or $\sqrt{\text{Ongoing}}$
CONDITIONS	(DD/MM/YYYY)	(DD/MM/YYYY)
CONDITIONS		
If the subject is currently taking any	y medications for a	ny of the above procedures, ensure that
details are recorded in the Concomi	tant Medications re	ecord.

	QUES	TIONNA	IRES
		YES	NO
Has analgesic and anti-inflammatory medications been			
NO	Questionnaires Completed	YES	NO
	2	natory medications been	

NHMRC Grant Approval Number 451900

Site Number:		Randomisation Number:	
Subject Initials:		Study Selected Knee:	
WOMAC			
NRS PAIN			

INCLUSION	CRITE	ERIA
	YES	NO
Is the subject aged 40 or over?		
Does the subject experience symptomatic knee osteoarthritis (ACR criteria)		
a) Knee pain (at least 20mm on NRS pain scale)		
b) An osteophyte on x-ray		
c) At least one of the following:		
- knee age greater than 50 years		
- stiffness lasting less than 30 minutes		
- crepitus		
Is the subject able to read, speak and understand English, capable of		
understanding the study requirements and willing to co-operate		_
with the study instructions?		
Is the subject able and willing to give informed consent?		
Has the subject used an investigational drug within 30 days of the screening visit?		
Is the subject willing and able to give blood samples		
Is the subject willing and able to have MRIs performed		
Is the subject willing and able to have DEXA scans performed?		
A tick recorded in any of the shaded boxes above signifies that the subject is ine should be excluded from entering the study	ligible a	nd

EXCLUSION CRITERIA YES NO

Site Number:	ation Number:				
Subject Initials:	cted Knee:				
	[]		
Does the subject suffer from dementia or be unable	e to give				
informed consent?					
Is the subject pregnant or breastfeeding, or is she u	nable or]		
unwilling to use an adequate method of contraception?					
Does the subject have Grade – 4 changes in their k	nee which is to]		
be investigated					
Has the subject ingested $\geq 10mL$ or ≥ 9 standard ca	psules of fish]		
oil daily for the proceeding 3 months					
Does the subject have any contra-indications for ha	aving MRIs or]		
DEXA scans performed?					
Does the subject have any clinically significant con	ndition(s) such				
as (but not limited to) cancer, rheumatoid arthritis,	psoratic				
arthritis, lupus or fibromyalgia? that in the opinion	of the				

should be excluded from entering the study	
	ENROLMENT CODE

with evaluation or preclude completion of the study A tick recorded in any of the shaded boxes above signifies that the subject is ineligible and

investigator may compromise their safety or compliance, interfere

If ALL inclusion and NO exclusion criteria have been met, the study subject may be assigned an enrolment code:

Ε				

PHYSICAL EX.	AMINATION/VITAL SIGNS
Height	cms
Weight	kgs
Blood Pressure	mmHG

Site Number:	
Subject Initials:	

Randomisation Number:

Study Selected Knee:

RUN	N-IN FISH	I OIL
	YES	NO
Has the run-in fish oil been supplied and explained?		
Has the dosing DVD been shown to the subject?		
Has the first dose of fish oil been taken under supervision in the		
clinic?		

PREVIOUS	S FISH (DIL USE
	YES	NO
Have you ever used fish oil prior to your involvement in this study?		
If yes, what was your average daily consumption of fish oil?		
Where 1 capsule OR 1 mL of liquid fish oil = $1g$		g/day

PREPARATION FOR NEXT A	PPOINTM	IENT
	YES	NO
Has a baseline/randomisation appointment been made?		
Has the subject been booked in for fasting blood tests prior to randomisation visit?		
Has the take home diary been supplied and explained?		
Has the subject been supplied with analgesic medication for pain relief? Make sure the details of this are recorded on the Paracetamol		
Accountability Sheet		

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:
	FOSTAR STUDY

Visit 2 (0 months) - RANDOMISATION

Visit Date	
DD / MM / YYYY	

	KNEE X-F	RAY
If not available at Visit 1, has an x-ray (no older than 12 months) of the study selected knee been assessed by the PI	YES	NO
 Does the subject meet knee inclusion criteria 1. Less than Grade – 4 changes in their study selected knee 2. An osteophyte on x-ray And at least one of the following: knee age greater than 50 years stiffness lasting less than 30 minutes crepitus 		

	STUDY SELECTED) KNEE
	LEFT	RIGHT
This subject's Study Selected knee is their		

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

	RUN-IN	FISH	OIL
		YES	NO
Was the run-in oil well tolerated?			
If not, describe the symptoms below:			
Any adverse events recorded here or in take-home diary to	ho trong	aribad	
Any adverse events recorded here of in take-nome diary to Adverse Events Record	be trans	cribeu	1 10
Auverse Events Record			
Has the run-in oil been returned			
Volume of the returned bottlemL			
volume of the retained bothe			
% of returned oil%			
(% = amount returned/amount supplied x 100)			
(// amount retained, amount suppried A 100)			
Was at least 75 % of expected run-in fish oil consumption conf	firmed?		
was at least 75 % of expected run-in fish on consumption com	IIIICu :		
Was tolerance and compliance adaquate?			
Was tolerance and compliance adequate?			
If no, withdraw subject			
If yes, continue with visit			

	ANAL	GESIC	USE
		YES	NO
Has subject withheld taking anti-inflammatory and analgesic			
medications prior to appointment			
If YES, continue with questionnaires.			
If NO, ask subject to withhold analgesic and inflammatory			

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:
medications from today and complete q	uestionnaires at home. The
questionnaires are then to be returned in	pre-paid envelopes.

	QUESTIONNAIRES				IRES
	Sup	plied	Comple		leted
	YES	NO		YES	NO
NRS pain / PGA					
Does the subject still meet pain inclusion criteria					
$(\geq$ score of 4 on NRS pain scale)					
If NO, withdraw the subject.					
If YES, continue					
WOMAC					
AQoL I					
MAPT					
Diet					
Diet Questionnaire Barcode					
Physical Activity (PASE)					

BLO	OD TH	ESTS
	YES	NO
Has a fasting blood sample been taken for FBC, MBA, CRP, fasting		
lipids (HDL, TGC, LDL)		
Has a serum pregnancy test been taken (if subject male, tick No box)		
Has a fasting blood sample been taken to measure serum fatty acids?		
Has a blood sample been taken for DNA sub-study?		

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

INCLUSION	I CRITI	ERIA
	YES	NO
Did the subject consume at least 75% of the expected volume of run- in fish oil		
Did the subject record a measurement of at least 20mm on the NRS pain scale for their study selected knee		
Does the subject still consent to taking part in the FOSTAR study		
Have knee x-rays, no older than 12 months old been reviewed		
 Does the subject meet inclusion criteria of: 1. Less than Grade – 4 changes in their study selected knee 2An osteophyte on x-ray 3. At least one of the following: knee age greater than 50 years stiffness lasting less than 30 minutes 4. crepitus 		
A tick recorded in any of the shaded boxes above signifies that the subject is ineli should be excluded from entering the study	gible and	1

	RANDOMISATION CODE
If ALL inclusion criteria have been met, th	e study subject may be assigned a
randomisation code:	R

Site Number:	Rando	omisation Number:
Subject Initials:	Study	Selected Knee:
		MEDICAL CHANGES
Has the subject been diagnosed	l with any NEW	<i>I</i> medical conditions since their last
visit?		
NEW MEDICAL	Date of Onset	Date Resolved Or $\sqrt{\text{Ongoing}}$
CONDITION	(DD/MM/YYYY)	(DD/MM/YYYY)

If the subject is currently taking any medications for any of the above conditions, ensure that details are recorded in the **Concomitant Medications record**.

CONCOMITANT MEDICATIONS						
Has the subject sta	Has the subject started, stopped or changed the doses of any medications since					
their last visit? (As	k to see	all medi	cations	used)		
Brand Name	Dose	Units	Route	Start/Stop Dates	Ongoing	
	(4)	(mg)	(po)	(DD/MM/YYYY)		
				Start//		
				Stop//		
				Start//		
				Stop//		
	Start/					
	Stop//					
				Start//		
				Stop//		
Please remember to transfer any details here to concomitant medications page						

HOSPITALISATIONS/DAY PROCEDURES						
Has the subject been to hospital for any medical procedures since their last visit?						
			\Box YES \Box NO			
If Yes, please pro	vide details below					
Date Admitted	Date	Doctor's Details	Purpose			
DD/MM/YYYY	Discharged					
	DD/MM/YYYY					
FOSTAR STUDY		NHMRC Grant	Approval Number 451900			

Site Number:		Randomisation Nu	mber:	
Subject Initials:		Study Selected Knee	2:	
Total Number of Hospitalisations since last visit:				

KNEE OSTEOARTHRITIS HISTORY	
With regard to the pain in your study-selected knee ;	
How long have you experienced pain in that knee?	years YES / NO
Have you had previous surgery to this knee	
If yes, what type of surgery?	\Box YES \Box NO
	Arthroscope
	☐ Meniscal Surgery
	Cartilage Surgery
	Tendon Surgery
	Ligament Surgery
	□ Other
If yes, when did you have surgery?	Date://

Site Number:	Randomisation Nu	mber:
Subject Initials:	Study Selected Kne	e:
Have you had a previous injury to this use of walking stick, frame or wheelcha	1 0	Yes No
If so, what year		Year:

	JOINT OSTEOARTHRITIS HISTORY
Over the past month have you had pain on most days in any of the following joints?	Other knee. Not the one being investigated in this study
	Lower Back
	□ Neck
	□ Shoulder
	☐ Hands
	Other (details)
	□ No others

	EDUCATION
What is highest level of education?	Didn't finish high school
	☐ Finished high school

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:
	Trade/Apprenticeship
	Certificate/Diploma
	□ Bachelor degree or higher
	Didn't answer

EMPLOYMENT HISTORY
☐ Full-time employed
Part-time/casual employment
Unemployed
Home Duties
Retired
Student
Other
Please specify

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:
What kind of work have you done for most of your life?	
(Study coordinator: please code into:-	
	☐ Manual
	Office/Professional
	□ Not Applicable

STUI	OY FISH	IOIL
	YES	NO
Has the study fish oil been supplied and explained		
Has the dosing DVD been shown to the subject (only if necessary)		
Has the take home diary been supplied and explained		

PHYSICAL EXAMINATION/VITAL SIGN	
Height (without shoes)	cms
Weight (without shoes, with clothes)	kgs
Blood Pressure (sitting, after resting for 5 minutes)	mmHG

ANALGESIC N	MEDICATION
Number of Paracetamol tablets supplied at previous visit	
Number of Paracetamol tablets returned	
Number of paracetamol tablets accounted for in diary	
Difference between number of tablets recorded taken and actual	
number of tablets removed from package.	

Site Number:	Randomisation Number:	
Subject Initials:	Study Selected Knee:	
Remember to remind Subject the importance of returning the empty foil strips. Remember to record these details in the Analgesic Medication Record		

PREPARATION FOR NEXT APPOINTMENT		ENT
	YES	NO
Has an appointment been made for the subjects DEXA scan		
Details://am/pm		
DD/MM/YYYY		
Has an appointment been made for the subjects MRI		
Details://am/pm		_
DD/MM/YYYY		
Has the subject been supplied an IMVS form for fasting bloods		
prior to next visit		
Has the subject been supplied with a FOSTAR fridge magnet		
Has the subject been supplied with a FOSTAR business card		
Has the subject been issued with a pedometer, had it's use		
explained and been asked to use it over a 7 day consecutive period?		
Please record details in Pedometer Record		
Has the subject been issued with analgesic medication for pain		
relief?		
Please ensure all details are recorded on the Analgesic medication		
Form		

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:
FOS	TAR STUDY

Visit 3 (3 months) - TREATMENT

Visit Date.....

DD / MM / YYYY

	ANALGESIC	USE
	YES	NO
Has subject withheld taking anti-inflammatory and		
analgesic medications prior to appointment		
If YES, continue with questionnaires.		
If NO, ask subject to withhold analgesic and inflammatory		
medications from today and complete questionnaires at		
home. The questionnaires are then to be returned in pre-		
paid envelopes.		

			QUESTION	INAI	RES
	Suı YES	oplied NO		Comp YES	
WOMAC					
AQol I					
NRS pain					

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

MEDICAL CHANGES				
Has the subject been diagnosed with any NEW medical conditions since their last				
visit?				
NEW MEDICAL	Date of Onset	Date Resolved Or $\sqrt{\text{Ongoing}}$		
CONDITION	(DD/MM/YY	(DD/MM/YYYY)		
	YY)			
If the subject is currently taking any medications for any of the above procedures, ensure that				
details are recorded in the Concomitant Medications record.				

CONCOMITANT MEDICATIONS					
Has the subject starte	Has the subject started, stopped or changed the doses of any medications since				
their last visit? (Ask	to see al	ll medica	ations used)	
Brand Name	Dose	Units	Route	Start/Stop Dates	Ongoing
				(DD/MM/YYYY)	
				Start//	
Stop//					
				Start//	
				Stop//	
Please remember to transfer any details here to concomitant medications page					

ANALGESIC	MEDICATION
Number of Paracetamol tablets supplied at previous visit	
Number of Paracetamol tablets returned	
Number of paracetamol tablets accounted for in diary	
Difference between number of tablets recorded taken and actual	

Site Number:	Randomisation Number:		
Subject Initials:	Study Selected Knee:		
number of tablets removed from packag	e.		
Remember to remind Subject the impor	tance of returning the empty	foil strips.	
Remember to record these details in the Analgesic Medication Record			

HOSPITALISATIONS/DAY PROCEDURES					
Has the subject	Has the subject been to hospital for any medical procedures since their last visit?				
	$\Box YES \Box NO$				
If Yes, please p	provide details belo	DW			
Date	Date	Doctor's Details	Purpose		
Admitted	Discharged		_		
DD/MM/YYYY	DD/MM/YYYY				
Т	Total Number of Hospitalisations since last Appointment:				

	BLOOD TI	ESTS
	YES	NO
Has a fasting blood sample been taken to measure serum fatty		
acids?		

Site Number:	
Subject Initials:	

Randomisation Number:

Study Selected Knee:


PHYSICAL EXAMINATION/VITAL SIGNS		
Height (without shoes)	cms	
Weight (without shoes, with clothes)	kgs	
Blood Pressure(sitting, after resting for 5 minutes)	mmHG	

	STUDY FIS	H OIL
	YES	NO
Has the Visit 2 fish oil been returned (inc. any empty bottles)		
How many mLs are remaining?mL		
What percentage of expected was taken?% (=amount actually taken/amount expected to be taken x 100)		
We want at least 75% compliance so if necessary, encourage subject to keep taking the fish oil on a daily basis		
Has Visit 3 fish oil been explained and supplied		

	VISIT 2 DI	ARY
	YES	NO
Has the subject's Visit 2 diary been collected and reviewed		
Have all diary concomitant medication records been		
transcribed into the CRFs Concomitant Medication Section		
Have all diary adverse event records been transcribed into the		
CRFs Adverse Events Section		

PREPARATION FOR NEXT APP	POINTM	IENT
	YES	NO
Has an appointment been made for the subjects next appointment in		

Site Number:	Randomisation Number:				
Subject Initials:	study Selected Knee:				
3 months time					
Details://am/pm	l				
DD/MM/YYYY					
Has the subject been supplied an IMVS for	orm for fasting bloods				
prior to next visit					
Has a Visit 3 take home diary been suppl	ied and explained				
Has the pedometer issued at Visit 2 been collected and the					
information recorded in the Pedometer Re					
Has the subject been issued with Analgesic medication to use for					
pain relief					
Please record this information on the Ana	lgesic Medication Form	L			



Visit 4 (6 months) - TREATMENT

Visit Date	
	DD / MM / YYYY

	ANALGESIC	USE
	YES	NO
Has subject withheld taking anti-inflammatory and analgesic		
medications prior to appointment		
If YES, continue with questionnaires.		
If NO, ask subject to withhold analgesic and inflammatory		
medications from today and complete questionnaires at		
home. The questionnaires are then to be returned in pre-paid		
envelopes.		

		QU	JESTIONNA	IRES	
	Sup	plied	Completed		
	YES	NO	YES	NO	
WOMAC					
AQol I					
NRS pain					

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

MEDICAL CHANGES					
Has the subject been diagnosed with any NEW medical conditions since their					
last visit?					
NEW MEDICAL	Date of Onset	Date Resolved Or $\sqrt{\text{Ongoing}}$			
CONDITION	(DD/MM/YYYY)	(DD/MM/YYYY)			
If the subject is currently taking any medications for any of the above procedures, ensure that					
details are recorded in the Concomitant Medications record.					

CONCOMITANT MEDICATIONS					
Has the subject	started,	stopped	or chang	ged the doses of any m	edications since
their last visit?	(Ask to s	see all m	edicatio	ns used)	
Brand Name	Dose	Units	Route	Start/Stop Dates	Ongoing
	(4)	(mg)	(po)	(DD/MM/YYYY)	
				Start//	
				Stop//	
				Start//	
				Stop//	
Please remember to transfer any details here to concomitant medications page					

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

HOSPITALISATIONS/DAY PROCEDURES							
Has the subject been to hospital for any medical procedures since their last visit?							
If Yes, please provid	le details below						
Date Admitted	Date Discharged	Doctor's Details	Purpose				
DD/MM/YYYY	DD/MM/YYYY						
Total Number of Hospitalisations since last visit:							

BLOOD TESTS		ESTS
	YES	NO
Has a fasting blood sample been taken to measure		
serum fatty acids?		

	PHYSICAL EXAMINATION/VITAL SIGNS		
Height (without shoes)		cms	
FOSTAR STUDY	NHMRC Grant Appro	NHMRC Grant Approval Number 451900	

Site Number:	Randomisation Number:]
Subject Initials:	Study Selected Knee:	
Weight (without shoes, with clothes)	kg	s
Blood Pressure (sitting, after resting for	5 minutes) mmHC	Ĵ

	STUDY FISH	I OIL
	YES	NO
Has the Visit 3 fish oil been returned (inc. any empty bottles)		
How many mLs are remaining?mL		
What percentage of expected was taken?% (=amount actually taken/amount expected to be taken x 100)		
We want at least 75% compliance so if necessary, encourage subject to keep taking the fish oil on a daily basis		
Has Visit 4 fish oil been explained and supplied		

ANALGESIC	C MEDICATION
Number of Paracetamol tablets supplied at previous visit	
Number of Paracetamol tablets returned	
Number of paracetamol tablets accounted for in diary	
Difference between number of tablets recorded taken and actual	
number of tablets removed from package.	
Remember to remind Subject the importance of returning the empty foil strips.	
Remember to record these details in the Analgesic Medication Record	

		VISIT 3 DI	ARY
		YES	NO
FOSTAR STUDY	NHMRC Grant Appro	val Number 451	900

NHMRC Grant Approval Number 451900

Site Number:	Randomisation Number:		
Subject Initials:	Study Selected Knee:		
Has the subject's Visit 3 diary been col	lected and reviewed		
Have all diary concomitant medication	records been		
transcribed into the CRFs Concomitant	Medication Section		
Have all diary adverse event records been transcribed into the			
CRFs Adverse Events Section			

PREPARATION FOR NEXT A	APPOINTM	IENT
	YES	NO
Has an appointment been made for the subjects next		
appointment in 3 months time?		
Details://am/pm		
DD/MM/YYYY		
Has the subject been supplied an IMVS form for fasting		
bloods prior to next visit?		
Has a Visit 4 take home diary been supplied and explained?		
Has the subject been supplied with analgesic medication for		
pain relief?		
Please record all details on the Analgesic Medication Form		

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:
	FOSTAR STUDY

Visit 5 (9 months) - TREATMENT

Visit Date	
	DD / MM / YYYY

	ANALGESIC	USE
	YES	NO
Has subject withheld taking anti-inflammatory and analgesic		
medications prior to appointment		
If YES, continue with questionnaires.		
If NO, ask subject to withhold analgesic and inflammatory		
medications from today and complete questionnaires at		
home. The questionnaires are then to be returned in pre-paid		
envelopes.		

		Q	UESTIONNA	IRES	
	Sup	Supplied Co		mpleted	
	YES	NO	YES	NO	
WOMAC					
AQol I					
NRS pain					

Site Number:	R
Subject Initials:	St

Randomisation Number:

Study Selected Knee:

MEDICAL CHANGES

Has the subject been diagnosed with any NEW medical conditions since their last visit?

NEW MEDICAL CONDITION	Date of Onset (DD/MM/YYYY)	Date Resolved Or √ Ongoing (DD/MM/YYYY)	
If the subject is currently taking any medications for any of the above procedures, ensure that details are recorded in the Concomitant Medications record.			

CONCOMITANT MEDICATIONS					
Has the subject started,	stopped	or change	ed the dos	es of any medications	s since
their last visit? (Ask to s	see all m	edication	s used)		
Brand Name	Dose	Units	Route	Start/Stop Dates	Ongoing
	(4)	(mg)	(po)	(DD/MM/YYYY)	
				Start//	
				Stop//	
				Start//	
				Stop//	
Please remember to transfer	any detai	ils here to c	oncomitant	medications page	

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

HOSPITALISATIONS/DAY PROCEDURES					
Has the subject been to hospital for any medical procedures since their last visit?					
			\Box YES \Box NO		
If Yes, please pro	vide details below				
Date	Date	Doctor's Details	Purpose		
Admitted	Discharged				
DD/MM/YYYY	DD/MM/YYYY				
Total Number of Hospitalisations since last Appointment:					

	BLOOD TESTS	
	YES	NO
Has a fasting blood sample been taken to measure serum fatty acids?		

	PHYSICAL EXAMINATIC	N/VITAL SIGNS
Height (without shoes)		cms
FOSTAR STUDY	NHMRC Grant Appro	oval Number 451900

Site Number:	Randomisation Number:	
Subject Initials:	Study Selected Knee:	
Weight (without shoes, with clothes)		kgs
Blood Pressure (sitting, after resting for	5 minutes)	mmHG

	STUDY FISH OIL		IOIL
		YES	NO
Has the Visit 4 fish oil been returned (inc. any empty bottles)			
How many mLs are remaining?mL			
What percentage of expected was taken?% (=amount actually taken/amount expected to be taken x 100)			
We want at least 75% compliance so if necessary, encourage subject to keep taking the fish oil on a daily basis			
Has Visit 5 fish oil been explained and supplied			

ANALGESIC	MEDICATION	
Number of Paracetamol tablets supplied at previous visit		
Number of Paracetamol tablets returned		
Number of paracetamol tablets accounted for in diary		
Difference between number of tablets recorded taken and actual		
number of tablets removed from package.		
Remember to remind Subject the importance of returning the empty foil strips.		
Remember to record these details in the Analgesic Medication Record		

	/ISIT 4 DI	ARY
	YES	NO
Has the subject's Visit 4 diary been collected and reviewed		
FOSTAR STUDY NHMRC Grant Approva	l Number 45	51900

Site Number:	Rand
Subject Initials:	Study
Have all diary concomitant medicati	on record

Randomisation Number:

Study Selected Knee:

Have all diary concomitant medication records been transcribed		
into the CRFs Concomitant Medication Section		
Have all diary adverse event records been transcribed into the		
CRFs Adverse Events Section		

PREPARATION FOR NEXT AF	POINTM	ENT
	YES	NO
Has an appointment been made for the subjects next appointment		
in 3 months time		
Details://am/pm		
DD/MM/YYYY		
Has the subject been supplied an IMVS form for fasting bloods		
prior to next visit		
Has a Visit 5 take home diary been supplied and explained		
Has the subject been issued with analgesic medication for pain		
relief		
Please record all details on the Analgesic Medication Form		

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:



Visit 6 (12 months) - TREATMENT

Visit Date	
	DD / MM / YYYY

	ANAI	LGESIC	USE
		YES	NO
Has subject withheld taking anti-inflammatory and analgesic			
medications prior to appointment			
If YES, continue with questionnaires.			
If NO, ask subject to withhold analgesic and inflammatory			
medications from today and complete questionnaires at home.	The		
questionnaires are then to be returned in pre-paid envelopes.			

	QUESTIONNAIRES			
	Supplied		Completed	
	YES	NO	YES	NO
WOMAC				
AQol I				
NRS pain				
MAPT				
Diet				
Diet Barcode				
Physical Activity (PASE)				

Store Store

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

		MEDICAL CHANGES		
Has the subject been diagnosed with any NEW medical conditions since their last				
visit?				
NEW MEDICAL	Date of Onset	Date Resolved Or $\sqrt{\text{Ongoing}}$		
CONDITION	(DD/MM/YYYY)	(DD/MM/YYYY)		
If the subject is currently taking any medications for any of the above procedures, ensure that				
details are recorded in the Concor	nitant Medications re	ecord.		

CONCOMITANT MEDICATIONS					
Has the subject starte	ed, stopp	bed or ch	anged the	doses of any medicatio	ns since
their last visit? (Ask	to see al	l medica	ations used)	
Brand Name	Dose	Units	Route	Start/Stop Dates	Ongoing
	(4)	(mg)	(po)	(DD/MM/YYYY)	
				Start//	
				Stop//	
				Start//	
				Stop//	
Please remember to transfer any details here to concomitant medications page					

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

HOSPITALISATIONS/DAY PROCEDURES						
Has the subject	Has the subject been to hospital for any medical procedures since their last visit?					
			YES	NO		
If Yes, please pro	vide details below					
Date	Date	Doctor's Details	Purpose			
Admitted	Discharged					
DD/MM/YYYY	DD/MM/YYYY					

Total number of hospital admissions since last visit:.....

	CURRENT EMPLOYMENT
What is your current work status?	☐ Full-time employed
	Part-time/casual employment
	Unemployed
	Home Duties
	Retired
	Student
	Other
	Please specify

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

J	OINT OSTEOARTHRITIS HISTORY
Over the past month have you had pain on most days in any of the following joints?	Other knee. Not the one being investigated in this study
	Lower Back
	□ Neck
	□ Shoulder
	☐ Hands
	Other (details)
	□ No others

BLC)OD TI	ESTS
	YES	NO
Has a fasting blood sample been taken to measure serum fatty acids?		

PHYSICAL EXAMINATION/VITAL SIGNS		
Height (without shoes)	cms	
Weight (without shoes, with clothes)	kgs	
Blood Pressure (sitting, after resting for 5 minutes)	mmHG	

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

S	STUDY FISH	HOIL
	YES	NO
Has the Visit 4 fish oil been returned (inc. any empty bottles)		
How many mLs are remaining?mL		
What percentage of expected was taken?% (=amount actually taken/amount expected to be taken x 100)		
We want at least 75% compliance so if necessary, encourage subject to keep taking the fish oil on a daily basis		
Has Visit 5 fish oil been explained and supplied		

ANALGESIC MEDICATION		
Number of Paracetamol tablets supplied at previous visit		
Number of Paracetamol tablets returned		
Number of paracetamol tablets accounted for in diary		
Difference between number of tablets recorded taken and actual		
number of tablets removed from package.		
Remember to remind Subject the importance of returning the empty foil strips.		
Remember to record these details in the Analgesic Medication Record		

	VISIT 5 DIARY	
	YES	NO
Has the subject's Visit 5 diary been collected and reviewed		
Have all diary concomitant medication records been transcribed		
into the CRFs Concomitant Medication Section		
Have all diary adverse event records been transcribed into the		
CRFs Adverse Events Section		

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

PREPARATION FOR NEXT APPOINTMENT		
	YES	NO
Has an appointment been made for the subjects next appointment in		
6 months time		
Details:/		
Has the subject been supplied an IMVS form for fasting bloods prior		
to next visit		
Has a Visit 6 take home diary been supplied and explained		
Has the subject been issued with a pedometer, had its use explained		
and been asked to use it for seven consecutive days.		
Please record details in Pedometer Record		
Has the subject been supplied with analgesic medication for pain		
relief?		
Please ensure all details are recorded on the Analgesic Medication		
Form		

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:
	FOSTAR STUDY

Visit 7 (18 months) - TREATMENT

	ANALGESIC	USE
	YES	NO
Has subject withheld taking anti-inflammatory and analgesic		
medications prior to appointment		
If YES, continue with questionnaires.		
If NO, ask subject to withhold analgesic and inflammatory		
medications from today and complete questionnaires at home.	,	
The questionnaires are then to be returned in pre-paid envelop	bes.	

QUESTIONNAIRES				IRES
	Supplied		Completed	
	YES	NO	YES	NO
WOMAC				
AQol I				
NRS pain				

DD / MM / YYYY

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

MEDICAL CHANGES				
Has the subject been diagnosed with any NEW medical conditions since their				
last visit?				
NEW MEDICAL	Date of Onset	Date Resolved Or $\sqrt{\text{Ongoing}}$		
CONDITION	(DD/MM/YYYY)	(DD/MM/YYYY)		
If the subject is currently taking any medications for any of the above procedures, ensure that				
details are recorded in the Concomitant Medications record.				

CONCOMITANT MEDICATIONS						
Has the subject started	, stoppe	d or cha	nged the	e doses of any medicatio	ns since	
their last visit? (Ask to	see all	medicat	ions use	d)		
Brand Name	Dose	Dose Units Route Start/Stop Dates Ongoing				
	(4)	(mg)	(po)	(DD/MM/YYYY)	(tick)	
	Start/ Stop//					
				Start//		
Please remember to transfer any details here to concomitant medications page						

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

HOSPITALISATIONS/DAY PROCEDURES						
Has the subject	Has the subject been to hospital for any medical procedures since their last visit?					
			□ YES □ NO			
If Yes, please p	provide details belo)W				
Date	Date	Doctor's Details	Purpose			
Admitted	Discharged					
DD/MM/YYYY	DD/MM/YYYY					
Total number of hospitalisations since last visit:						

	BLOOD T	ESTS
	YES	NO
Has a fasting blood sample been taken to measure serum fatty		
acids?		

PHYSICAL EXAMINATION/VITAL SIGN	
Height (without shoes)	cms
Weight (without shoes, with clothes)	kgs
Blood Pressure (sitting, after resting for 5 minutes)	mmHG

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

ST	TUDY FISH	IOIL
	YES	NO
Has the Visit 6 fish oil been returned (inc. any empty bottles)		
How many mLs are remaining?mL		
What percentage of expected was taken?% (=amount actually taken/amount expected to be taken x 100)		
We want at least 75% compliance so if necessary, encourage subject to keep taking the fish oil on a daily basis		
Has Visit 7 fish oil been explained and supplied		

ANALGESIC N	MEDICATION	
Number of Paracetamol tablets supplied at previous visit		
Number of Paracetamol tablets returned		
Number of paracetamol tablets accounted for in diary		
Difference between number of tablets recorded taken and actual		
number of tablets removed from package.		
Remember to remind Subject the importance of returning the empty foil strips.		
Remember to record these details in the Analgesic Medication Reco	ord	

VIS	SIT 6 DL	ARY
	YES	NO
Has the subject's Visit 6 diary been collected and reviewed		
Have all diary concomitant medication records been transcribed		
into the CRFs Concomitant Medication Section		
Have all diary adverse event records been transcribed into the CRFs		
Adverse Events Section		

Site Number:	Randomisation Numb	ber:	
Subject Initials:	Study Selected Knee:		

PREPARATION FOR NEXT APPO	INTM	ENT
	YES	NO
Has an appointment been made for the subjects next appointment in		
6 months time		
Details://am/pm		
DD/MM/YYYY		
Has the subject been supplied an IMVS form for fasting bloods prior		
to next visit		
Has a Visit 7 take home diary been supplied and explained		
Has the pedometer that was issued to the subject at Visit 6 been		
returned and the details transcribed to the Pedometer record Section		
Has the subject had a pedometer issued, had its use explained and		
been asked to use the pedometer over 7 consecutive days. Please		
record details in Pedometer Record Section of CRF		
Has the subject been issued with analgesic medication for pain relief?		
Please ensure all details are recorded on the Analgesic Medication		
Form		
	•	

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:



FOSTAR STUDY

Visit 8 (24 months) – Completion/Withdrawal

Visit	
Date	
	DD / MM / YYYY

AN	ALGESIC	USE
	YES	NO
Has subject withheld taking anti-inflammatory and analgesic		
medications prior to appointment		
If YES, continue with questionnaires.		
If NO, ask subject to withhold analgesic and inflammatory		
medications from today and complete questionnaires at home. The		
questionnaires are then to be returned in pre-paid envelopes.		

	QU	ESTIC	ONNAI	RES
			Completed	
	YES	NO		NO
WOMAC				
AQol I				
NRS pain				
MAPT				

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:
Diet	
Diet Barcode	
Physical Activity (PASE)	

		MEDICAL CHANGES	
Has the subject been diagnosed with any NEW medical conditions since their last			
visit?			
NEW MEDICAL	Date of Onset	Date Resolved Or $\sqrt{\text{Ongoing}}$	
CONDITION	(DD/MM/YYYY)	(DD/MM/YYYY)	
If the subject is currently taking any medications for any of the above procedures, ensure that			
details are recorded in the Concomitant Medications record.			

CONCOMITANT MEDICATIONS					
Has the subject started, stopped or changed the doses of any medications since their			s since their		
last visit? (Ask to see	all medi	cations u	ised)		
Brand Name	Dose	Units	Route	Start/Stop Dates	Ongoing
	(4)	(mg)	(po)	(DD/MM/YYYY)	
				Start//	
Stop//					
Start/					
				Stop//	
Please remember to transfer any details here to concomitant medications page					

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

		HOSPITALISATI	ONS/DAY PROCEDURES	
Has the subject	Has the subject been to hospital for any medical procedures since their last visit?			
			YES NO	
If Yes, please p	provide details belo)W		
Date	Date	Doctor's Details	Purpose	
Admitted	Discharged			
DD/MM/YYYY	DD/MM/YYYY			
Total Number of Hospitalisations since last visit:				

JOIN	T OSTEOARTHRITIS HISTORY
Over the past month have you had pain on most days in any of the following joints?	Other knee. Not the one being investigated in this study
	Lower Back
	□ Neck
	☐ Shoulder
	☐ Hands

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:
	 Other (details) No others
	(details)
	\Box No others

	CURRENT EMPLOYMENT
What is your current work status?	☐ Full-time employed
	Part-time/casual employment
	Unemployed
	Home Duties
	Retired
	Student
	Other
	Please specify

	BLOOD T	ESTS
	YES	NO
Has a fasting blood sample been taken to measure serum fatty acids?		
Has a fasting blood sample been taken for FBC, MBA, CRP, fasting lipids (HDL, TGC, LDL)		
Has a serum pregnancy test been taken (if subject male, tick No box)		

PHYSICAL EXAMINAT	ION/VITAL SIGNS
Height (without shoes)	cms
Weight (without shoes, with clothes)	kgs
Blood Pressure (sitting, after resting for 5 minutes)	mmHG

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

	STUDY FISH OIL	
	YES	NO
Has the Visit 7 fish oil been returned (inc. all empty bottles)		
How many mLs are remaining?mL		
What percentage of expected was taken?% (=amount actually taken/amount expected to be taken x 100)		
We want at least 75% compliance so if necessary, encourage subject to keep taking the fish oil on a daily basis		

ANALGESIC	MEDICATION
Number of Paracetamol tablets supplied at previous visit	
Number of Paracetamol tablets returned	
Number of paracetamol tablets accounted for in diary	
Difference between number of tablets recorded taken and actual	
number of tablets removed from package.	
Remember to remind Subject the importance of returning the empty foil strips.	
Remember to record these details in the Analgesic Medication Record	

VISIT 7 DIARY		ARY
	YES	NO
Has the subject's Visit 7 diary been collected and reviewed		
Have all diary concomitant medication records been transcribed into		
the CRFs Concomitant Medication Section		
Have all diary adverse event records been transcribed into the CRFs		
Adverse Events Section		

Site Number:	Randomisation Number:
Subject Initials:	Study Selected Knee:

FINALISING THE STU		UDY
	YES	NO
Has an appointment been made for the subjects final DEXA scan on		
their study selected knee?		
Details://am/pm		
DD/MM/YYYY		
Has an appointment been made for the subjects final MRI on their		
study selected knee?		
Details://am/pm		
DD/MM/YYYY		
Has an appointment been made for the subjects x-ray on their study		
selected knee?		
Details:/		
DD/MM/YYYY		
Has the subject been sincerely thanked for their time, effort and		
cooperation during the study?		
Has the pedometer that was issued to the subject at their last visit		
been returned?		
Please record all details in the Pedometer Record Section of the CRF		
Has the subject's Hospital records been updated to show that they		
have completed/withdrawn from the study?		
Has a letter been sent to the subject's GP to notify their Dr of their		
completion/withdrawal from the study?		